These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

6269 related items for PubMed ID: 2654950

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Association between induction of anti high molecular weight-melanoma associated antigen (HMW-MAA) immunity with mouse antiidiotypic monoclonal antibody (MoAb) MK2-23 and prolongation of survival in patients with melanoma.
    Chen ZJ, Yang H, Liu CC, Mittelman A, Ferrone S.
    Pigment Cell Res; 1992; Suppl 2():113-22. PubMed ID: 1409413
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Systemic treatment for renal cell carcinoma: an overview.
    Swanson DA.
    Prog Clin Biol Res; 1990; 350():201-25. PubMed ID: 2201044
    [No Abstract] [Full Text] [Related]

  • 7. Cytokine-based therapy for melanoma: pre-clinical studies.
    Shurin MR, Kirkwood JM, Esche C.
    Forum (Genova); 2000; 10(3):204-26. PubMed ID: 11007930
    [Abstract] [Full Text] [Related]

  • 8. Ganglioside antigens expressed by human cancer cells.
    Ritter G, Livingston PO.
    Semin Cancer Biol; 1991 Dec; 2(6):401-9. PubMed ID: 1810468
    [Abstract] [Full Text] [Related]

  • 9. Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside.
    Houghton AN, Bajorin DF, Lonberg M, Chapman P.
    Prog Clin Biol Res; 1989 Dec; 288():383-90. PubMed ID: 2654956
    [No Abstract] [Full Text] [Related]

  • 10. Antibody-interleukin 2 fusion proteins: a new approach to cancer therapy.
    Reisfeld RA, Gillies SD.
    J Clin Lab Anal; 1996 Dec; 10(3):160-6. PubMed ID: 8731505
    [No Abstract] [Full Text] [Related]

  • 11. [Immunotherapy of parenchymal tumors. Recent progress and theoretical considerations].
    Marincola F, Smolik L, Annoni F, Holter WD.
    Minerva Chir; 1988 Jul 31; 43(13-14):1111-31. PubMed ID: 3054627
    [No Abstract] [Full Text] [Related]

  • 12. CTLA-4 blockade: autoimmunity as treatment.
    Kapadia D, Fong L.
    J Clin Oncol; 2005 Dec 10; 23(35):8926-8. PubMed ID: 16204008
    [No Abstract] [Full Text] [Related]

  • 13. Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma.
    Kim TS, Cohen EP.
    Cancer Res; 1994 May 15; 54(10):2531-5. PubMed ID: 8168073
    [Abstract] [Full Text] [Related]

  • 14. Suppression of human melanoma growth in nude mice injected with anti high-molecular-weight melanoma-associated antigen monoclonal antibody 225.28S conjugated to purothionin.
    Matsui M, Nakanishi T, Noguchi T, Imai K, Yachi A, Ferrone S.
    Jpn J Cancer Res; 1985 Feb 15; 76(2):119-23. PubMed ID: 3920101
    [Abstract] [Full Text] [Related]

  • 15. Kinetics of the immune response and regression of metastatic lesions following development of humoral anti-high molecular weight-melanoma associated antigen immunity in three patients with advanced malignant melanoma immunized with mouse antiidiotypic monoclonal antibody MK2-23.
    Mittelman A, Chen ZJ, Liu CC, Hirai S, Ferrone S.
    Cancer Res; 1994 Jan 15; 54(2):415-21. PubMed ID: 8275478
    [Abstract] [Full Text] [Related]

  • 16. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O, Russello O, Leenen C, Diehl V, Bohlen H, Berthold F.
    Med Pediatr Oncol; 2001 Jan 15; 36(1):185-9. PubMed ID: 11464879
    [Abstract] [Full Text] [Related]

  • 17. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
    Cancer Res; 1986 Feb 15; 46(2):676-83. PubMed ID: 3484431
    [Abstract] [Full Text] [Related]

  • 18. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K.
    Clin Cancer Res; 2009 Mar 01; 15(5):1623-34. PubMed ID: 19208793
    [Abstract] [Full Text] [Related]

  • 19. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
    Kawashima I, Yoshida Y, Taya C, Shitara H, Yonekawa H, Karasuyama H, Tada N, Furukawa K, Tai T.
    Int J Oncol; 2003 Aug 01; 23(2):381-8. PubMed ID: 12851687
    [Abstract] [Full Text] [Related]

  • 20. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
    Riemer AB, Förster-Waldl E, Brämswig KH, Pollak A, Zielinski CC, Pehamberger H, Lode HN, Scheiner O, Jensen-Jarolim E.
    Eur J Immunol; 2006 May 01; 36(5):1267-74. PubMed ID: 16568495
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 314.